Nucleoside analogs with carboxamidine modified monocyclic base

Abstract

Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.

1 . A method of treating a condition in a patient comprising:
 administering a compound according to Formula 1   
     
       
         
         
             
             
         
       
       wherein the compound is in L-configuration. 
     
   
   
       2 . A method of treating a condition in a patient comprising:
 administering a pro-drug form of the compound according to Formula 1,   
     
       
         
         
             
             
         
       
       wherein the compound is in L-configuration or D-configuration. 
     
   
   
       3 . The method of  claim 1 , wherein the condition is selected from the group consisting of an HIV infection, an HCV infection, a n HBV infection, and a Human Papilloma Virus infection. 
   
   
       4 . The method of  claim 1  wherein the condition comprises a liver disease. 
   
   
       5 . The method of  claim 1 , wherein the step of administering increases a Type 1 response relative to a Type 2 response in the patient. 
   
   
       6 . The method of  claim 1 , wherein the step of administering comprises oral administration. 
   
   
       7 . The method of  claim 1 , wherein the step of administering comprises administering the compound in a dose between 0.1 mg per kg of body weight of the patient and 1.0 mg per kg of body weight of the patient. 
   
   
       8 . The method of  claim 2 , wherein the condition is selected from the group consisting of an HIV infection, an HCV infection, a n HBV infection, and a Human Papilloma Virus infection. 
   
   
       9 . The method of  claim 2  wherein the condition comprises a liver disease. 
   
   
       10 . The method of  claim 2 , wherein the step of administering increases a Type 1 response relative to a Type 2 response in the patient. 
   
   
       11 . The method of  claim 2 , wherein the step of administering comprises oral administration. 
   
   
       12 . The method of  claim 2 , wherein the step of administering comprises administering the compound in a dose between 0.1 mg per kg of body weight of the patient and 1.0 mg per kg of body weight of the patient.